CA
NZ
UK
AU
IND
US
● NextCure shares have fallen sharply, most recently closing at $6.25, down 7.82%, as the market continues repricing the stock around its pendingReverse mergerwith Avere Therapeutics.
● Phathom Pharmaceuticals shares have fallen, most recently closing at $8.60, down 7.73%, after Q2 2026 results showed VOQUEZNA netRevenueof about $74.3 million, up roughly 88% year over year.
● Picard Medical shares have fallen, most recently closing at $3.03, down 7.90%, near the bottom of a range distorted by a recent 1-for-50 reverse stock split.
● Lantern Pharma shares have fallen sharply, most recently closing at $2.29, down 8.03%, after Q2 2026 net loss of roughly $7.1 million, or $(0.57) per share, missed consensus.
● MapLight Therapeutics shares have fallen, most recently closing at $11.23, down 7.57%, following disclosure of a $150 million privatePlacementat $11.38 per share.
● Kardigan shares have fallen sharply, most recently closing at $20.26, down 7.95%, without a fresh company-specific catalyst identified about ten days after its Q2 2026 report.
● Kyverna Therapeutics shares have fallen sharply, most recently closing at $8.13, down 8.34%, after an earlier rally driven by positive Phase 2 stiff person syndrome data showing a median 46% improvement in the timed 25-foot walk test.
● HCWBiologicsshares have fallen, most recently closing at $2.12, down 7.83%, with a marketCapitalizationof roughly $3.9 million.
● Immatics shares have fallen, most recently closing at $8.55, down 7.57%, following a report showing an operating loss in the neighborhood of EUR120 million andRevenuebelow consensus.
● Perspective Therapeutics shares have fallen, most recently closing at $3.21, down 7.76%, consolidating after a strong 2026 advance.
Please wait processing your request...